Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a
Milan, Italy, July 1, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Ad hoc announcement pursuant to Art. 53 LR
Interim results show improved symptoms of psychosis in patients with chronic TRS
Study 014 represents first international trial of a New
Milan, Italy – April 5, 2022 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, March 15, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
